A section of the A548 coast road in North Wales has been closed as emergency services are respond to a large fire. North Wales Fire and Rescue Service said crews are currently tackling the blaze in Greenfield, Holywell, North Wales Police said the fire is in a derelict building. The force said the A548 Mostyn Road is shut and drivers are being asked to keep away from the area. This is a breaking news story. Further updates as we have them will be shared in the blog below Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you. If you have some information you can contact us by following our Twitter feed @northwaleslive - the official North Wales Live account - real news in real time. Or like facebook.com/northwaleslive/ - your must-see news, features, videos and pictures throughout the day from the North Wales Live. Don't forget you can also keep up to date with the latest via the free North Wales Live app. Download it for Apple devices here and Android devices here . North Wales Live has launched a WhatsApp community group where you can get the latest stories delivered straight to your phone Roadside sensors show some traffic congestion in the area. At this time of the day, traffic volumes are, of course, typically much lower. Social media reports suggest the building involved is the former Morfa Newydd residential home, which closed in early 2023. However, this has not yet been officially confirmed. North Wales Police also issued a statement, advising people to stay clear.... The road is currently closed on the A548 Mostyn Road, Greenfield, Holywell, due to a fire at a derelict building. Please avoid the area, thank you North Wales Fire and Rescue Service said its crews are at the scene. A spokesperson said.... Firefighters are tackling a large building fire in Greenfield. Please avoid the coast road area whilst emergency services deal with the incident. Good evening, we'll bring you updates on this incident as soon as we have them.
LOS ANGELES — Northern California is being drenched by the first major atmospheric river storm of the season, with rain totals reaching well over 7 inches in many areas, and continued rain on Thursday stretching the threat for flooding and mudslides. The slow-moving storm was strengthened by a so-called bomb cyclone, which describes how rapidly the system intensified in the Pacific before it moved ashore. By Friday, the rain will begin moving southward, and while forecasters are saying some rain is likely to hit Southern California by the weekend, it will be dramatically less than than what's been seen north of the Bay Area this week. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get the latest news, sports, weather and more delivered right to your inbox.
Hiker dies in White Mountains after falling in icy conditions
None
Rolling out new criminal laws CAA major tasks of MHA in 2024While Novo Nordisk 's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself "Ozempic Santa," he wasn't taking Ozempic. Reports indicate he was actually taking Eli Lilly 's ( LLY -1.38% ) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock is up about 36% year to date as of this writing and has gained around 506% over the past five years. Given the stock's strong performance, the natural question becomes whether the stock is still a buy going forward. Let's see if the momentum can continue. A GLP-1 powerhouse While Ozempic has more brand recognition, Eli Lilly's Mounjaro and Zepbound have proven better clinically at helping patients lose weight. The two Eli Lilly drugs use the same active ingredient -- tirzepatide -- but they are approved for different indications. Mounjaro is approved to help adult patients with type 2 diabetes improve blood glucose levels, while Zepbound is approved to help weight loss in obese adults or overweight adults with at least one weight-related condition (such as type 2 diabetes, high blood pressure, or high cholesterol). Regardless of what they are approved for, however, many non-obese people are using these drugs to lose weight. One example is the already mentioned Elon Musk using Mounjaro, which is technically approved for type-2 diabetes patients. Off-label use of GLP-1 drugs to lose weight has become rampant, helping drive shortages of the drugs and profits for the companies that make them. Meanwhile, a study earlier this year found that Mounjaro was superior to Ozempic in helping people lose weight with similar side effects. The study involved 18,000 people and showed that patients taking Mounjaro were twice as likely to lose 5% of their body weight, 2.5 times as likely to lose 10% of their body weight, and more than three times as likely to lose 15% of their body weight as patients taking Ozempic. Meanwhile, after being on the drug for six months, patients on average lost 10% of their body weight using Mounjaro versus 6% for patients prescribed Ozempic. Novo Nordisk, the maker of Ozempic, has questioned the reported results, saying the optimal dosage for weight loss for its drug was not released. However, Mounjaro is getting a following, with Musk saying he preferred the drug because it was more effective with fewer side effects for him, adding Ozempic made him "fart and burp like Barney from The Simpsons ." Eli Lilly's GLP-1 drugs, meanwhile, have been powering the company's results. Last quarter, Mounjaro revenue more than doubled year over year to $3.11 billion, while Zepbound added an additional $1.26 billion in revenue after being introduced in Q4 of 2023. The company's overall revenue climbed 20%, while its adjusted earnings per share skyrocketed from $0.10 a year ago to $1.18. Excluding a divestiture, revenue would have climbed 42% year over year. Looking ahead, Eli Lilly sees revenue growth accelerating to 50% year over year in Q4, powered by increased production capacity and the launch of Mounjaro in new international markets. The company has been pouring money into increasing capacity, and will also begin to increase spending on demand generation. Since 2020, Eli Lilly has announced more than $20 billion in commitments to build, upgrade, and acquire manufacturing facilities. Is the stock a buy? GLP-1 weight-loss drugs are not the only drugs Eli Lilly is selling and developing. In fact, the rest of its portfolio was solid, with revenue last quarter up 17% for non-incretin drugs, excluding its dispositions. That said, it is these weight-loss drugs that will largely drive its results and the stock moving forward. The company continues to have a big opportunity in front of it, as it looks to continue to increase supply to meet the strong demand. Meanwhile, it is launching the drugs in new international markets and there have been calls for Medicare and Medicaid to expand coverage for the drugs under their programs. Zepbound also just got approval for use in obese patients with moderate to severe obstructive sleep apnea, which opens up a new market for the drug. From a valuation perspective, the stock trades at a forward price-to-earnings (P/E) ratio of 35 times next year's analyst estimates, with a price/earnings-to-growth (PEG) ratio of only 0.6. PEGs under 1 are considered undervalued, so the stock is very attractively valued on that basis. Data by YCharts. Eli Lilly is not without risks. Compounders had been selling cheaper versions of GLP-1 drugs under a shortage exemption, and while Lilly's active ingredient was taken off the exemption list this month, semaglutide (the active ingredient in Ozempic) and liraglutide (the active ingredient in Saxenda) are still on it, which leads to low-price competition. Meanwhile, companies such as Hims & Hers have argued they can still make these compound drugs even after the shortage issues are resolved as there is a well-established precedence of being allowed to sell personalized versions of drugs that can reduce side effects for individual users. Hims & Hers uses personalized medications across its drug portfolio, so a legal battle could be brewing. For its part, Lilly has teamed with Hims & Hers' competitor Ro to offer cheaper prices for Zepbound and to better compete with the compounders. The $400 to $550 per month price is still high, and it also speaks to the risk of potential price pressure these drugs could face. Meanwhile, Musk, who's gained a lot of political influence, said nothing could improve the health of Americans more than offering GLP-1 drugs at super-low prices. While a potential pushback on high GLP-1 drug prices is a risk, for now, this is a stock with huge growth at an attractive valuation. This makes it a solid buy candidate.
How Trump’s bet on voters electing him managed to silence some of his legal woes
Malik Nabers says calling the Giants 'soft' was wrong but he doesn't regret speaking outMicrosoft is taking away the Xbox Avatar EditorBorisa Simanic, the Serbian basketball player who suffered a severe kidney injury during the 2023 World Cup, is back in action. His impressive return comes after a significant recovery process, culminating in helping Serbia clinch a spot in the upcoming EuroBasket tournament. Playing in Belgrade for the first time since the incident, Simanic scored 12 essential points leading Serbia to a dominant 98-51 victory over Denmark. This win secured them as the sixth team qualified for the championship, joining Lithuania and host nations Latvia, Finland, Cyprus, and Poland. With 18 spots still open, competition remains fierce. The journey has been nothing short of remarkable; losing a kidney during a match with South Sudan almost ended his career, but Simanic's determination saw him return swiftly. Supported by fellow Serbian player Nikola Jovic, he has been competing in the Adriatic League and now sets his sights on EuroBasket glory. (With inputs from agencies.)
The Chemours Company ( NYSE:CC – Get Free Report ) has earned an average rating of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $24.88. A number of equities analysts have weighed in on CC shares. BMO Capital Markets increased their target price on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, October 7th. Morgan Stanley cut their price objective on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a report on Tuesday, November 5th. The Goldman Sachs Group lowered their target price on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, September 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Chemours in a report on Thursday, December 12th. Finally, Barclays lifted their price target on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Get Our Latest Stock Report on CC Insider Buying and Selling Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its stake in Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the last quarter. Matrix Trust Co bought a new stake in Chemours in the 3rd quarter worth approximately $25,000. Truvestments Capital LLC purchased a new stake in Chemours in the third quarter worth approximately $35,000. Brooklyn Investment Group purchased a new position in shares of Chemours during the third quarter worth approximately $37,000. Finally, Signaturefd LLC lifted its holdings in shares of Chemours by 163.7% in the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock worth $40,000 after acquiring an additional 1,216 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors. Chemours Trading Down 1.8 % NYSE:CC opened at $17.01 on Friday. The firm’s 50 day moving average is $19.49 and its 200 day moving average is $20.36. Chemours has a 12 month low of $15.10 and a 12 month high of $32.70. The stock has a market capitalization of $2.54 billion, a PE ratio of 34.02 and a beta of 1.80. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. Chemours ( NYSE:CC – Get Free Report ) last issued its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts expect that Chemours will post 1.35 earnings per share for the current year. Chemours Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 5.88%. The ex-dividend date of this dividend was Friday, November 15th. Chemours’s dividend payout ratio is 200.00%. About Chemours ( Get Free Report The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. Further Reading Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter .Who are the 10 biggest UK lottery winners?First American Financial Co. (NYSE:FAF) Receives Average Rating of “Moderate Buy” from Brokerages
Chuck Woolery , whose game-show hosting career included tenures at Wheel of Fortune and Love Connection , has died at age 83. Mark Young, Woolery’s friend and podcast cohost, shared the news on X on Saturday. “It is with a broken heart that I tell you that my dear brother @chuckwoolery has just passed away,” Young wrote. “Life will not be the same without him. RIP, brother.” Young told TMZ he was at Woolery’s home in Texas when the former TV host reported not feeling well and went to lie down. When Young checked in later, Woolery was having trouble breathing, and despite a 911 call, Woolery died shortly thereafter. Woolery was born on March 16, 1941, in Ashland, Kentucky, to a business owner and a homemaker, according to The Hollywood Reporter . After stints at the University of Kentucky, in the U.S. Navy, and at Morehead State University, Woolery moved to Nashville to start a music career. He and singer Elkin “Bubba” Fowler formed the psychedelic pop duo The Avant-Garde, and their song “Naturally Stoned” peaked at No. 40 on the Billboard Hot 100 in 1968. Lorimar Television/ Everett Collection A singing performance on The Merv Griffin Show led Woolery to audition for a new game show, originally titled Shopper’s Bazaar , that Merv Griffin was developing at the time. After some tinkering, Wheel of Fortune debuted on NBC on January 6, 1975. Griffin earned a Daytime Emmy for his Wheel work and hosted the show until 1981, when a salary dispute led producers to replace him with Pat Sajak . ‘Wheel of Fortune’ Turns 40, But Do You Remember the Other Versions? Woolery moved on with a job hosting the syndicated dating game show Love Connection from 1983 to 1994, pulling in 4.5 million viewers a day at one point. He also emceed the game show Scrabble from 1984 to 1990, and between the two shows, he was earning $1 million a year by 1986, as People reported at the time. Woolery also hosted the game show Greed on Fox from 1999 to 2000 and Lingo on Game Show Network from 2002 to 2007. In recent years, Woolery stoked controversy with his political views, posting a tweet that sparked antisemitism accusations in 2017 and then claiming in 2020 that “everyone [was] lying” about the coronavirus pandemic , as Newsweek reported. He also argued that minorities didn’t need civil rights, according to the Associated Press . Woolery was married four times, and his ex-wives included actor Jo Ann Pflug. He had eight children and stepchildren, per THR . More Headlines: Chuck Woolery Dies: Former ‘Wheel of Fortune’ and ‘Love Connection’ Host Was 83 Will Ryan Eggold Return for ‘Cross’ Season 2? Chad Duell Leaving ‘General Hospital’: ‘This Wasn’t an Easy Decision for Me’ ‘The White Lotus’: Everything We Know About a Possible Season 4 ‘Brilliant Minds’ Scoop on ‘Terrifying’ Cliffhanger, Plus What’s Next With Carol’s Patient?Opinion: Portland’s monuments should include the writers who inspire us